BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix Inc (BDSX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong revenue growth, improved gross margins, reduced losses, and strategic partnerships indicate a solid growth trajectory. Despite overbought technical indicators, the long-term potential outweighs short-term fluctuations.
The stock shows bullish momentum with MACD above zero, RSI at 80.338 (overbought), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The price is above key support levels, with resistance at R1: 16.661 and R2: 17.947. However, the overbought RSI suggests caution for short-term traders.
Q4 2025 revenue increased by 40.76% YoY, surpassing expectations.
Gross margin improved to 83%, reflecting better cost control.
Strategic partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories enhance product pipeline and market expansion.
Hedge funds are significantly increasing their positions, with a 1991.20% increase in buying activity.
Analysts have upgraded the stock, citing strong execution and improved financials.
Insiders are selling, with a 531.80% increase in selling activity over the last month.
The stock is overbought based on RSI, suggesting potential short-term pullback.
The company reported a net loss of $3.98 million in Q4 2025, though it has improved YoY.
In Q4 2025, revenue grew by 40.76% YoY to $28.76 million, gross margin improved to 83%, and net losses reduced by 51.76% YoY to -$3.98 million. EPS improved but remains negative at -$0.49. The company is showing strong operational efficiency and growth momentum.
William Blair upgraded Biodesix to Outperform from Market Perform, citing strong execution, improved financials, and momentum heading into 2026. The company's 2026 revenue guidance is 3% ahead of expectations.
